Related references
Note: Only part of the references are listed.Patient Satisfaction with 20% Subcutaneous Immunoglobulin (Hizentra®) Treatment: Results From a Single-Center Study in Children with Immunodeficiencies
Clare Malcolmson et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Experience with a 20% Subcutaneous Immunoglobulin (Hizentra®) in Children with Primary Immunodeficiency Diseases - A Single-Center Review
Rebecca Gregory et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Bioavailability of IgG Administered by the Subcutaneous Route
Melvin Berger et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2013)
Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies
Melvin Berger et al.
CLINICAL IMMUNOLOGY (2011)
Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy
S. Jolles et al.
CLINICAL IMMUNOLOGY (2011)
Impact of Pharmacometric Analyses on New Drug Approval and Labelling Decisions A Review of 198 Submissions Between 2000 and 2008
Joo Yeon Lee et al.
CLINICAL PHARMACOKINETICS (2011)
Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease
Richard L. Wasserman et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2011)
Efficacy and Safety of Subcutaneous VivaglobinA® Replacement Therapy in Previously Untreated Patients with Primary Immunodeficiency: A Prospective, Multicenter Study
Michael Borte et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2011)
Pharmacokinetic and Pharmacodynamic Basis for Effective Argatroban Dosing in Pediatrics
Rajanikanth Madabushi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease
R. L. Wasserman et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency
John B. Hagan et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2010)
The Emerging Scientific Discipline of Pharmacometrics
Marc Pfister et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Clinical pharmacokinetics of bevacizumab in patients with solid tumors
Jian-Feng Lu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies
R. Gustafson et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2008)
Pharmacokinetics of Immunoglobulin Administered via Intravenous or Subcutaneous Routes
Francisco A. Bonilla
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA (2008)
Optimising piperacillin/tazobactam dosing in paediatrics
Christoffer W. Tornoe et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2007)
Applications of population pharmacokinetics in current drug labelling
J. Z. Duan
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2007)
Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases
Hans D. Ochs et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2006)
Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer
R Bruno et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis
DS Yim et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Primary immunodeficiency diseases: An update
L Notarangelo et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)
Primary immunodeficiency diseases due to defects in lymphocytes.
RH Buckley
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
